All In Biotech

Drug Trial Radar · NCT07745114

SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of SAL0137 Tablets in Healthy Participants With or Without Elevated Lp(a)

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Jan 4, 2026

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is divided into 3 parts: Part A, Part B, and Part C. Part A is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of SAL0137 tablets; Part B is a randomized, double-blind, placebo-controlled, multiple ascending dose study with once-daily administration for 14 consecutive days to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple QD oral doses of SAL0137 tablets.

Conditions

  • Healthy Participants
  • Elevated Lp(a)

Interventions

  • Single Ascending DoseDrug

    SAL0137

  • Single Ascending DoseDrug

    Placebo

  • Once Daily (QD), Multiple Ascending Dose (MAD)Drug

    SAL0137

  • Once Daily (QD), Multiple Ascending Dose (MAD)Drug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Security IndexTime frame: Throughout the entire experiment, an average of 6 to 11 weeks.
  2. Security IndexTime frame: Throughout the entire experiment, an average of 6 to 11 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of ANHUI Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.